TRPV1 and bone neoplasm: TRPV1 was initially evaluated in bone cancer pain in 2005, revealing that most sensory neurons in malignant bone expressed TRPV1, and subcutaneous treatment of its antagonist, JNJ-17203212, mitigated pain-related behaviors.